Heparin, Low-Molecular-Weight
"Heparin, Low-Molecular-Weight" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.
| Descriptor ID |
D006495
|
| MeSH Number(s) |
D09.698.373.400.300
|
| Concept/Terms |
Heparin, Low-Molecular-Weight- Heparin, Low-Molecular-Weight
- Heparin, Low Molecular Weight
- LMWH
- Low Molecular Weight Heparin
- Low-Molecular-Weight Heparin
|
Below are MeSH descriptors whose meaning is more general than "Heparin, Low-Molecular-Weight".
Below are MeSH descriptors whose meaning is more specific than "Heparin, Low-Molecular-Weight".
This graph shows the total number of publications written about "Heparin, Low-Molecular-Weight" by people in this website by year, and whether "Heparin, Low-Molecular-Weight" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 1 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 3 | 0 | 3 |
| 2004 | 0 | 4 | 4 |
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 4 | 4 |
| 2009 | 1 | 3 | 4 |
| 2010 | 1 | 2 | 3 |
| 2016 | 0 | 2 | 2 |
| 2017 | 1 | 1 | 2 |
| 2019 | 1 | 1 | 2 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Heparin, Low-Molecular-Weight" by people in Profiles.
-
Unfractionated and Low-Molecular-Weight Heparin for Bridging Patients with Left Ventricular Assist Device: An Event-Based Analysis. ASAIO J. 2021 12 01; 67(12):1277-1283.
-
Effectiveness and Safety of Twice- Versus Thrice-Daily Subcutaneous Heparin for Venous Thromboembolism Prophylaxis at a Large Academic Medical Center. Ann Pharmacother. 2022 05; 56(5):541-547.
-
Controversies in anticoagulation therapy in patients with cirrhosis. Curr Opin Gastroenterol. 2019 05; 35(3):161-167.
-
Symptomatic Venous Thromboembolism After Adolescent Knee Arthroscopy. J Pediatr Orthop. 2019 Mar; 39(3):125-129.
-
Cerebral Venous Sinus Thrombosis Due to Low-molecular-weight Heparin-induced Thrombocytopenia. Neurologist. 2017 Nov; 22(6):241-244.
-
Cerebral sinus venous thrombosis during childhood acute lymphoblastic leukemia therapy: Risk factors and management. Pediatr Blood Cancer. 2017 Dec; 64(12).
-
Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism. Pharmacotherapy. 2016 10; 36(10):1109-1115.
-
Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis. Nat Commun. 2016 Mar 21; 7:11037.
-
Improvement in long-term ECMO by detailed monitoring of anticoagulation: a case report. Perfusion. 2011 Jan; 26(1):59-64.
-
DVT prophylaxis: better living through chemistry: affirms. Orthopedics. 2010 Sep 07; 33(9):642.